Genomewide Screen Identifies Peroxisomal Role in APOL1 Podocytopathy

  • 0Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH.

Summary

This summary is machine-generated.

The APOL1 gene variants linked to chronic kidney disease (CKD) are worsened by hypoxia. Peroxisome function is key, as enhancing it reduces cell death, suggesting a new therapeutic target for CKD.

Area Of Science

  • Genetics
  • Cell Biology
  • Nephrology

Background

  • The APOL1 gene G1 and G2 variants are risk factors for chronic kidney disease (CKD) in individuals of African descent.
  • Secondary stressors like hypoxia exacerbate APOL1 variant-induced podocyte dysfunction and cell death through incompletely understood mechanisms.

Purpose Of The Study

  • To identify genes influencing the cytotoxic effects of APOL1 variants under hypoxic conditions.
  • To elucidate the role of peroxisomes in APOL1-related kidney disease pathogenesis.

Main Methods

  • Conducted a whole-genome RNA interference (RNAi) screen to identify genes modulating APOL1 variant cytotoxicity.
  • Utilized genetic and pharmacological approaches to enhance peroxisomal function.
  • Identified and mutated a peroxisomal targeting signal (PTS) in APOL1.

Main Results

  • Silencing of several peroxisomal (PEX) genes significantly intensified APOL1 variant-induced cytotoxicity.
  • Enhanced peroxisomal function, genetically or pharmacologically, markedly reduced APOL1 variant cytotoxicity.
  • A C-terminal peroxisomal targeting signal (PTS) in APOL1 was identified; mutations in this signal attenuated variant cytotoxicity.

Conclusions

  • Peroxisomal function plays a critical, previously unrecognized role in the pathogenesis of APOL1-associated CKD.
  • Targeting peroxisomes presents a potential therapeutic strategy to reduce CKD risk in populations carrying APOL1 risk variants.